Table 1.
Demographic and clinical characteristics of study subjects
| Subject characteristic | Value for subjects 2 to 5 yr old |
Value for subjects 6 to 17 yr old |
||||
|---|---|---|---|---|---|---|
| WC-rBS vaccineesa (n = 20) | Cholera patients (n = 20) | P | WC-rBS vaccineesa (n = 20) | Cholera patients (n = 18) | P | |
| No. that completed 30-day follow-up | 18 | 18 | 20 | 17 | ||
| Mean age (yr [range]) | 4.7 (3–5) | 4.2 (2–5) | NSb | 10.5 (7–14) | 9.9 (6–16) | NS |
| Female (no. [%]) | 9 (45) | 10 (50) | NS | 10 (50) | 7 (39) | NS |
| ABO blood group (no. [%]) | ||||||
| A | 5 (25) | 3 (15) | NS | 4 (20) | 5 (28) | NS |
| B | 4 (20) | 4 (20) | NS | 6 (30) | 7 (39) | NS |
| AB | 2 (10) | 1 (5) | NS | 3 (15) | 1 (6) | NS |
| O | 9 (45) | 12 (60) | NS | 7 (35) | 5 (28) | NS |
a
WC-rBS, whole-cell recombinant B subunit oral cholera vaccine (Dukoral, Crucell, Sweden); n, number of participants.
b
NS, nonsignificant.